Liberia: $117 million to finance integrated interventions against HIV, tuberculosis, strengthening of resilient health systems, covid-19 and malaria

Liberian President Joseph Nyuma Boakai has launched the seventh round of Global Fund grants (GC7), worth more than $117 million. The information was published in a press release issued by the Liberian Coordinating Mechanism (LCM), the body that coordinates Global Fund investments in the country, on 11 July 2024. 

The grant is intended to finance integrated interventions against HIV, tuberculosis, strengthening resilient health systems, covid-19 and malaria. It covers the period 2024-2026, and comes at a time when the country launched a malaria vaccine for children aged between 5 and 18 months in April 2024. 

‘Our commitment is to improve healthcare and to train and build the capacity of healthcare professionals to ensure that they have the necessary skills,’ said Mr Boakai. 

According to a WHO report dating from 2022, Liberia’s progress in the fight against HIV/AIDS is currently 66% for screening, 93% for treatment and 76% for care. The number of tuberculosis cases per 100,000 inhabitants has fallen from 240 in 2000 to 308 in 2022. 

With this new funding, the Global Fund’s cumulative disbursement to Liberia has reached $391.58 million since 2004, according to the LCM secretariat.